

Pharmacist Training Program for Long-Acting Injectables

Tuesday, January 30, 2024

Ohio Pharmacists Association

2674 Federated Blvd. • Columbus, Ohio 43235

The Ohio Pharmacists Association was instrumental in the passage of SB 332 which allows Ohio pharmacists to administer the following dangerous drugs by injection:

- 1) Opioid antagonist used for treatment of drug addiction or alcohol dependence and administered in long-acting or extended-release form;
- 2) Antipsychotic drug administered in long-acting or extended-release form;
- 3) Hydroxyprogesterone caproate for pregnant women;
- 4) Medroxyprogesterone acetate for non-pregnant women;
- 5) Cobalamin.

Pharmacists who plan to administer these dangerous drugs must:

- complete a course in the administration of drugs that meets the requirements in Ohio Administrative Code 4729:1-3-03(L);
- receive and maintain certification to perform basic life-support procedures by completing a basic life-support training course certified by the American Red Cross, American Heart Association or other training course approved by the board of pharmacy;
- practice in accordance with a protocol established by a physician and which satisfies the requirements established in rules adopted by the state board of pharmacy.

Goals. The goals of this program are to train pharmacists in the use of long-acting injectable (LAI) antipsychotics and opioid antagonists; train pharmacists to properly administer these medications; provide strategies for practice implementation; and review the tests necessary prior to administration of an opioid antagonist and evaluation of the test results. Participants must demonstrate proper sterile technique and administration of both IM and SC injections during the program.

Objectives. At the conclusion of this activity, participants will be able to:

1. list the FDA-approved indications for long-acting injectable (LAI) antipsychotics and naltrexone;

This program meets training requirements established by State of Ohio Board of Pharmacy rule 4729:1-3-03(L) to qualify pharmacists to administer LAI antipsychotics and to administer LAI opioid antagonists for the treatment of opioid and alcohol dependence.

2. describe the mechanism of action, appropriate dose, contraindications, warnings, and adverse reactions of LAI antipsychotics and naltrexone;

3. discuss appropriate patient populations and the importance of ensuring patient privacy during administration of LAI antipsychotics and naltrexone;

4. compare and contrast LAI antipsychotics by dose, frequency, administration, and requirement for oral supplementation;

5. describe the evidence for naltrexone LAI in treating opioid dependence;

6. compare the efficacy of naltrexone LAI to buprenorphine and methadone for treating opioid and alcohol dependence;

7. evaluate and document the appropriate tests prior to the administration of naltrexone LAI;

8. outline acute and chronic monitoring parameters and treatment of the patient for adverse reactions for each of these dangerous drugs, including use of diphenhydramine and epinephrine;

9. demonstrate proper sterile technique in injectable dosage preparation and administration of intramuscular and subcutaneous injections;

10. explain the proper disposal procedures for contaminated needles and dangerous drugs, and the proper procedures for accidental needle sticks; and

11. discuss practice implementation strategies.

Faculty

Chris Paxos, PharmD, BCPP
Mary Borovicka, PharmD, BCPP
Muriel O'Connell, MS, RN
Leigh Anne Meyer, MS, DNP, RN

Program Schedule

8:00 am	Registration
8:30-10:30 am	Review of Long-Acting Injectable Antipsychotics and Pharmacist Administration
10:30-10:45 am	Break
10:45-12:45 pm	Naltrexone and Buprenorphine Extended-Release Injections
12:45-1:15 pm	Lunch
1:15-3:30 pm	Sterile Technique in Dosage Preparation and Administration
3:30 pm	Adjournment

Pharmacist Training Program for Long-Acting Injectables

Tuesday, January 30, 2024 • OPA Office • Columbus, OH

Name _____ Nickname for Badge _____

NABP e-Profile ID _____ Birthdate (MMDD format) _____

Preferred Mailing Address home work _____

City _____ State _____ Zip _____

Place of Employment _____

Home Phone_(_____) _____ Work Phone_(_____) _____

Fax_(_____) _____ E-mail _____

Special Dietary Requirements low fat vegetarian If physically impaired, indicate special needs _____

Registration Fee: Live CE, Homestudy
OPA Member \$295
Non-member \$425
Resident (PGY1 or PGY2) \$265

Total Remitted \$ _____
 MasterCard VISA American Express
Account Number _____

Mail to: Ohio Pharmacists Foundation
2674 Federated Blvd., Columbus, OH 43235

Exp. Date _____ Security Code _____

Or **Register Online** at www.ohiopharmacists.org

Name on Card _____

Or **Fax** with credit card information:
614.389.4582

Billing Address if different from above:

Or **Call** with credit card information:
614.389.3236

Requests for refunds, less \$25 administrative fee, will be honored if received by 1/23/2024.

This program includes live training (0.6 CEU), two home-study lessons (0.2 CEU each) for a total of 1.0 CEU, and draft protocols for LAI antipsychotics and naltrexone/buprenorphine.

Certificate of Achievement. To become eligible to receive a Certificate of Achievement for this program and to meet State of Ohio Board of Pharmacy criteria, participants must:

- complete the two home-study activities with a passing grade of at least 80% for each activity:
(*Long-Acting Injectable Antipsychotics Review for Pharmacists*, ACPE 0129-0000-21-079-H01-P, 0.2 CEU;
Review of Injectable Extended-Release Naltrexone and Buprenorphine, ACPE 0129-0000-21-080-H01-P, 0.2 CEU);
- successfully complete the live training session, ACPE 0129-0000-21-081-L01-P, 0.6 CEU; and
- show proof of current certification in CPR; if not yet certified, complete a CPR course through your local American Red Cross or American Heart Association chapter.

To receive CPE credit for the live training session, pharmacists must attend the full session; administer IM and SC injections; demonstrate successful comprehension of program content; and complete the CPE/evaluation form and return it to OPF staff. CPE credit will be uploaded to the CPE Monitor. The Certificate of Achievement for this program will be generated when all portions of the program are completed.



The Ohio Pharmacists Foundation (OPF) provides educational programs for pharmacists and consumers of health care that enhance the practice of pharmacy and patient outcomes. This program is targeted to pharmacists in all practice settings. Individuals responsible for planning OPF continuing pharmacy education activities have no relevant financial relationships with ineligible companies to disclose.

0129-0000-21-079-H01-P is a knowledge-based activity
0129-0000-21-080-H01-P is a knowledge-based activity
0129-0000-21-081-L01-P is an application-based activity



The Ohio Pharmacists Foundation Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.